We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




POC Lateral Flow Test Detects Deadly Fungal Infection Faster Than Existing Techniques

By LabMedica International staff writers
Posted on 19 Jun 2025

Diagnosing mucormycosis—an aggressive and often deadly fungal infection—remains a major challenge due to the disease’s rapid progression and the lack of fast, accurate diagnostic tools. More...

The problem became especially severe during the COVID-19 pandemic, when infections surged globally, particularly in India. Now, a novel lateral-flow test offers a potential solution by enabling rapid detection of mucormycosis directly from patient biofluids.

The test was developed by scientists at the University of Exeter (Exeter, UK), who aimed to address the urgent need for quicker and more reliable diagnostics for mucormycosis. Before the pandemic, the disease was rare and typically limited to immunocompromised individuals. However, COVID-19 created ideal conditions for the spread of mucormycosis—also known as rhino-orbital-cerebral mucormycosis (ROCM)—due to widespread corticosteroid use, high rates of poorly managed diabetes, and associated metabolic imbalances such as diabetic ketoacidosis. These conditions severely impair the body’s ability to fend off fungal infections, leading to a dramatic spike in cases. The new lateral-flow test represents a significant innovation over traditional diagnostic methods, which rely on culturing biopsy samples in laboratories—a process that is not only time-consuming but also has low sensitivity. In contrast, the Exeter-developed test delivers results in just 30 minutes.

The test works by using a specific antibody that binds to a signature molecule secreted by Mucorales fungi. This interaction generates a visible signal, indicating the presence of the pathogen directly from a patient's biofluid sample. In a study published in the Journal of Clinical Microbiology, researchers tested the new diagnostic among three groups: patients with mucormycosis, patients with other fungal infections, and patients without fungal infections. The test showed high sensitivity and specificity, accurately identifying mucormycosis cases in just half an hour. Although still in the prototype phase, these results highlight its potential as a dependable and swift screening tool. If adopted widely, the lateral-flow test could have a transformative impact on clinical practice. It would allow for early detection of mucormycosis, improving the chances of timely treatment and potentially reducing the risk of disfigurement and death. This could be especially beneficial in regions with limited access to advanced laboratory infrastructure, offering a life-saving tool in the ongoing fight against this fast-moving fungal disease.

“Mucormycosis is an horrific disease, which spreads rapidly in the body and can leave people horribly facially disfigured, and is often fatal. Early diagnosis is crucial for the best outcome,” said Professor Chris Thornton, a scientist at the University of Exeter’s MRC Centre for Medical Mycology and co-author of the study. “This study shows that our new test is quick and effective. These exciting results are a critical milestone in the development and validation of the test which we aim to commercialize in the next three years.”

Related Links:
University of Exeter’s MRC Centre for Medical Mycology


New
Gold Member
Hybrid Pipette
SWITCH
Collection and Transport System
PurSafe Plus®
ESR Analyzer
TEST1 2.0
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.